Incyte Corporation (BIT:1INCY)

Italy flag Italy · Delayed Price · Currency is EUR
57.50
0.00 (0.00%)
Last updated: May 29, 2025
17.06%
Market Cap 11.10B
Revenue (ttm) 4.08B
Net Income (ttm) 19.68M
Shares Out n/a
EPS (ttm) 0.09
PE Ratio 563.99
Forward PE 10.79
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 29
Open 57.50
Previous Close 57.50
Day's Range 57.50 - 57.50
52-Week Range 47.33 - 79.44
Beta n/a
RSI 68.84
Earnings Date Jul 29, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 2,617
Stock Exchange Borsa Italiana
Ticker Symbol 1INCY
Full Company Profile

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD Financial Statements

News

There is no news available yet.